AI Article Synopsis
- The study aimed to explore the effectiveness of 3-indolylmethanamines 31B and PS121912 in treating ovarian cancer and leukemia, respectively.
- Various methods, including TUNEL and western blotting, were used to analyze apoptosis and tumor growth in mice models.
- The results indicated that compound 31B successfully inhibited ovarian cancer cell proliferation and tumor growth without toxicity, while also impacting glucose metabolism, highlighting the potential of 3-indolylmethanamines as a new class of antitumor agents.
Article Abstract
Aim: To investigate the in vivo effects of 3-indolylmethanamines 31B and PS121912 in treating ovarian cancer and leukemia, respectively.
Materials And Methods: Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) and western blotting were applied to demonstrate the induction of apoptosis. Xenografted mice were investigated to show the antitumor effects of 3-indolylmethanamines. (13)C-Nuclear magnetic resource (NMR) and western blotting were used to demonstrate inhibition of glucose metabolism.
Results: 31B inhibited ovarian cancer cell proliferation and activated caspase-3, cleaved poly (ADP-ribose) polymerase 1 (PARP1), and phosphorylated mitogen-activated protein kinases (MAPK), JUN N-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38. 31B reduced ovarian cancer xenograft tumor growth and PS121912 inhibited the growth of HL-60-derived xenografts without any sign of toxicity. Compound 31B inhibited de novo glycolysis and lipogenesis mediated by the reduction of fatty acid synthase and lactate dehydrogenase-A expression.
Conclusion: 3-Indolylmethanamines represent a new class of antitumor agents. We have shown for the first time the in vivo anticancer effects of 3-indolylmethanamines 31B and PS121912.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633305 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Antitumor Activity of 3-Indolylmethanamines 31B and PS121912.
Anticancer Res
November 2015
Department of Chemistry and Biochemistry, University of Wisconsin, Milwaukee, WI, U.S.A. Milwaukee Institute of Drug Discovery, University of Wisconsin, Milwaukee, WI, U.S.A.
Article Synopsis
- The study aimed to explore the effectiveness of 3-indolylmethanamines 31B and PS121912 in treating ovarian cancer and leukemia, respectively.
- Various methods, including TUNEL and western blotting, were used to analyze apoptosis and tumor growth in mice models.
- The results indicated that compound 31B successfully inhibited ovarian cancer cell proliferation and tumor growth without toxicity, while also impacting glucose metabolism, highlighting the potential of 3-indolylmethanamines as a new class of antitumor agents.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!